Canada Markets open in 4 hrs 54 mins

Advaxis, Inc. (ADXS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1496-0.0034 (-2.22%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1530
Open0.1427
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range0.1400 - 0.1530
52 Week Range0.1210 - 1.5700
Volume378,523
Avg. Volume4,110,843
Market Cap21.787M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.1710
Earnings DateJan. 20, 2022 - Jan. 24, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

    Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients in Part C, with ADXS-503 being dosed in combination with pembrolizumab in first line MONMOUTH JUNCTION, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the de

  • GlobeNewswire

    Advaxis Announces Acceptance for Trading on the OTCQX

    MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has satisfied the requirements for trading of the Company’s common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on December 23, 2021 under the symbol ADXS. The Company previously traded on Nasdaq. OTCQX is the

  • GlobeNewswire

    Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

    Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that following the conclusion of its second reconvened special meeting of stockholders on December 16, 20